Title and Organization:
Greg Yap, MBA, is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, patient-focused digital health, and transformative technologies. Previously, Greg was an entrepreneur-in-residence at Illumina Ventures, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: Biodesy, a next generation protein analysis company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million revenue per year. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company. He also serves on the board of Outward Bound California. Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. Greg’s current investments include Clear Labs, Encoded Therapeutics, Epiodyne, Pliant Therapeutics, Sana Health, and Senti Bio. He is a San Francisco Bay Area native and lives in Palo Alto, CA, with his wife and children. Greg is a Fellow of the fifth class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.